76 / 164
336
[REV. MED. CLIN. CONDES - 2015; 26(3) 325-337]
control study between extrapleural pneumonectomy and
radical pleurectomy/decortication for pathological N2
malignant pleural mesothelioma. Eur J Cardiothorac Surg.
2007 May;31:765-70.
71.
Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural
pneumonectomy versus no extra-pleural pneumonectomy
for patients with malignant pleural mesothelioma: clinical
outcomes of the Mesothelioma and Radical Surgery (MARS)
randomised feasibility study. Lancet Oncol. 2011;12:763-72.
72.
Weder W, Stahel RA, Baas P, et al. The MARS feasibility
trial: conclusions not supported by data.Lancet Oncol.
2011;12:1093-4; author reply 4-5.
73.
Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/
decortication is superior to extrapleural pneumonectomy in
the multimodality management of patients with malignant
pleural mesothelioma. J Thorac Oncol. 2012;7:737–743.
74.
Minatel E, Trovo M, Polesel J, et al. Tomotherapy after
pleurectomy/decortication or biopsy for malignant pleural
mesothelioma allows the delivery of high dose of radiation in
patients with intact lung. J Thorac Oncol. 2012;7:1862-6.
75.
Price A. What is the role of radiotherapy in malignant pleural
mesothelioma? Oncologist. 2011;16:359-65.
76.
de Graaf-Strukowska L, van der Zee J, van Putten W, Senan
S. Factors influencing the outcome of radiotherapy in
malignant mesothelioma of the pleura--a single-institution
experience with 189 patients. Int J Radiat Oncol Biol
Phys.1999;43:511-6.
77.
Jenkins P, Milliner R, Salmon C. Re-evaluating the role of
palliative radiotherapy in malignant pleural mesothelioma.
Eur J Cancer. 2011;47:2143-9.
78.
Low EM, Khoury GG, Matthews AW, Neville E. Prevention of
tumour seeding following thoracoscopy in mesothelioma
by prophylactic radiotherapy. Clin Oncol (R Coll Radiol).
1995;7:317-8.
79.
De Ruysscher D, Slotman B. Treatment of intervention sites
of malignant pleural mesothelioma with radiotherapy: a
Dutch-Belgian survey. Radiother Oncol. 2003;68:299-302.
80.
Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van Meerbeeck
J. Advances in the systemic therapy of malignant pleural
mesothelioma. Nat Clin Pract Oncol. 2008;5:136-47.
81.
Nowak
AK.
Chemotherapy
for
malignant
pleural
mesothelioma: a review of current management and a look
to the future. Ann Cardiothorac Surg. 2012;1:508-15.
82.
Jakobsen JN, Sorensen JB. Review on clinical trials of targeted
treatments in malignant mesothelioma. Cancer Chemother
Pharmacol. 2011;68:1-15.
83.
Hassan R, Sharon E, Pastan I. Mesothelin targeted chemo-
immunotherapy for treatment of malignant mesothelioma
and lung adenocarcinoma. Ann Oncol. 2010;21:ii42.
84.
Wong RM, Ianculescu I, Sharma S, et al. Immunotherapy for
malignant pleural mesothelioma. Current status and future
prospects. Am J Respir Cell Mol Biol. 2014 May;50(5):870-875.
85.
Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative
dendritic cell-based immunotherapy elicits cytotoxicity
against malignant mesothelioma. Am J Respir Crit Care Med.
2010;181:1383-90.
86.
Astoul P, Roca E, Gallateau-Salle F, Scherpereel A. Malignant
pleural mesothelioma. From the bench to the bedside.
Respiration. 2012;83:481-93.
87.
Kim H, Gao W, Ho M. Novel immunocytokine IL12-SS1 (Fv)
inhibits mesothelioma tumor growth in nude mice. PLoS One.
2013;8:e81919.
88.
Rodriguez-Panadero F, Montes-Worboys A. Mechanisms of
pleurodesis. Respiration. 2012;83:91-8.
89.
Bielsa S, Hernández P, Rodriguez-Panadero F, Taberner T,
Salud A, Porcel JM. Tumor type influences the effectiveness of
pleurodesis in malignant effusions. Lung. 2011;189:151-5.
90.
Gottehrer A1, Taryle DA, Reed CE, Sahn SA. Pleural fluid
analysis inmalignant mesothelioma. Prognostic implications.
Chest. 1991 Oct;100(4):1003-6.
91.
Rodríguez-Panadero F, López Mejías J. Low glucose and pH
levels in malignant pleural effusions. Diagnostic significance
and prognostic value in respect to pleurodesis. Am Rev Respir
Dis. 1989 Mar;139(3):663-7.
92.
Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible
carbonic anhydrase IX and XII promote tumor cell growth
by counteracting acidosis through the regulation of the
intracellular pH. Cancer Res 2009;69: 358–368.
93.
Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies R. Acid-
mediated tumor invasion: A multidisciplinary study. Cancer
Res 2006;66: 5216–23.
94.
Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH
dynamics and the Na+/H+ exchanger in metastasis. Nat Rev
Cancer 2005;5: 786–795.
95.
Chiche J, Brahimi-Horn C, Pouysségur J. Tumour hipoxia
induces a metabolic shift causing acidosis: A common feature
in cáncer. J Cell Mol Med 2010;14,4:771-94.
96.
Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell
DA. Expression and prognostic significance of hypoxia-
inducible factor 1alpha (HIF-1alpha) in malignant pleural
mesothelioma (MPM). Lung Cancer. 2006 Jan;51(1):53-9.
97.
Echevarría M, Muñoz-Cabello AM, Sánchez-Silva R, Toledo-
Aral JJ, López-Barneo J. Development of cytosolic hypoxia
and hypoxia-inducible factor stabilization are facilitated by
aquaporin-1 expression. J Biol Chem 2007;282: 30207–
30215.
98.
Parks SK1, Chiche J, Pouyssegur J. pH control mechanisms
of tumor survival and growth. J Cell Physiol. 2011
Feb;226(2):299-308.
99.
Cases E, Seijo L, Disdier C, et al. Uso del drenaje pleural
permanente en el manejo ambulatorio del derrame pleural
maligno recidivante. Arch Bronconeumol. 2009;45:591-6.
100. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety
of tunneled pleural catheters in adults with malignant
pleural effusions: a systematic review. J Gen Intern Med.
2011;26:70-6.
101. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling
pleural catheter vs chest tube and talc pleurodesis for